Coronavirus Disease 2019 (COVID-19) remains a threat with the emergence of new variants, especially Delta and Omicron, without specific effective therapeutic drugs. The present invention provides a method and a composition for preventing and treating COVID-19 (SARS-CoV-2) coronavirus infection which includes administering to a subject in need thereof one or more therapeutically effective doses of Virofree which comprises a pharmaceutically acceptable combination of grape seed extract, acerola cherry extract, olive leaf extract, marigold extract, green tea extract, pomegranate extract, yeast beta-glucan and soya bean extract for a treatment period.

The disclosure is a composition for treating, preventing, ameliorating, or suppressing cancer, or inhibiting cancer metastasis, comprising a plant fermentation extract as an active ingredient, wherein the plant fermentation extract comprises a yeast that is viable in an environment at pH 1 and that is capable of forming spores in a complete medium.

The disclosure is a composition for treating, preventing, ameliorating, or suppressing cancer, or inhibiting cancer metastasis, comprising a plant fermentation extract as an active ingredient, wherein the plant fermentation extract comprises a yeast that is viable in an environment at pH 1 and that is capable of forming spores in a complete medium.

The present invention relates to compositions comprising one or more compounds and/or extracts which induce, promote and/or improve production/release/delivery/excretion of mucin from and/or in the cornea, and methods of using the compositions to treat the eye.

The present invention relates to compositions comprising one or more compounds and/or extracts which induce, promote and/or improve production/release/delivery/excretion of mucin from and/or in the cornea, and methods of using the compositions to treat the eye.

This invention relates to the use of probiotic yeast cells that produce recombinant parathormone for therapeutic purposes, where probiotic cells that produce rhPTH developed for use in hypoparathyroidism treatment are first microencapsulated, placed into gelatin capsules and then orally administrated.

This invention relates to the use of probiotic yeast cells that produce recombinant parathormone for therapeutic purposes, where probiotic cells that produce rhPTH developed for use in hypoparathyroidism treatment are first microencapsulated, placed into gelatin capsules and then orally administrated.

The present disclosure is directed towards skin care compositions, skin care formulations, and methods for providing treatment of scalp disorders. More specifically, the present disclosure is directed towards methods and compositions comprising at least one microorganism of the genus Yarrowia and/or a fraction thereof, and/or a cell lysate thereof, and/or fermentate thereof, and/or metabolite thereof, for treating a scalp disorder, including dandruff.

The present disclosure is directed towards skin care compositions, skin care formulations, and methods for providing treatment of scalp disorders. More specifically, the present disclosure is directed towards methods and compositions comprising at least one microorganism of the genus Yarrowia and/or a fraction thereof, and/or a cell lysate thereof, and/or fermentate thereof, and/or metabolite thereof, for treating a scalp disorder, including dandruff.

The present disclosure is directed towards a method of treating a disease or condition associated with gut inflammation. The present disclosure comprises administering, to a patient in need thereof, a composition comprising oxygen-scavenging membrane fragments or membrane vesicles. In some embodiments, membrane vesicles are derived from bacteria. In some embodiments, membrane vesicles are derived from the cytoplasmic membranes of Escherichia coli, Salmonella typhimurium, Gluconobacter oxydans, Pseudomonas aeruginosa, or Acetobacter.